EC Number   |
Application |
Reference |
|---|
   2.7.11.24 | analysis |
a concept and implementation of a new simple inhibitor screening method applicable for a broad range of human proteins by using transformed bacteria is reported |
701666 |
| 2.7.11.24 | analysis |
crystal structure of the MAP kinase binding domain of human MAP kinase phosphatase MKP5 |
682741 |
| 2.7.11.24 | analysis |
development of a protein chip consisting of a silicone elastomer microwell array with recombinant enzyme covalently attached to the wells via a 3-glycidoxypropyltrimethoxysilane crosslinker for large scale activity assay, overview |
662926 |
| 2.7.11.24 | analysis |
HitHunter EFC binding assay can be used to select compounds that specifically target inactive kinase |
677890 |
| 2.7.11.24 | analysis |
the use of 3'-UTR elements to regulate tissue-specific expression of pmk-2 provides a mechanism that endows context specificity to p38 paralogues |
740759 |
| 2.7.11.24 | drug development |
Echinococcus multilocularis MPK2 is a promising target for the development of drugs against alveolar echinococcosis |
690853 |
| 2.7.11.24 | drug development |
kinase inhibitors modulate proliferation of leukemia cells, the MEK/ERK inhibitor, PD098059, in combination with either SP600125, an inhibitor of N-terminal c-jun kinases, or LY294002, a PI3K inhibitor, could have clinical value |
679691 |
| 2.7.11.24 | drug development |
MAPKs are targets for drug development |
666322 |
| 2.7.11.24 | drug development |
p38 MAPK inhibitors have significant therapeutic potential for the treatment of rheumatoid arthritis, inflammatory bowel disease, osteoporosis, and many other diseases where aberrant cytokine signaling is the driver of disease |
693569 |
| 2.7.11.24 | medicine |
c-Jun N-terminal kinase might be another therapeutic target in liver neoplasms |
704909 |
